Anthera Pharmaceuticals raises $19M for anti-inflammatory drugs
Anthera Pharmaceuticals has raised $19 million in a second round of funding led by Caxton Advantage Life Sciences Fund and HBM BioCapital. Existing investors VantagePoint Venture Partners, Sofinnova Ventures, Pappas Ventures and Mitsubishi International Corporation also participated.
The San Mateo, Calif. company is developing treatments for inflammatory diseases and autoimmune disorders. told VentureWire that its lead treatment, Varespladib, is directed at cardiovascular patients and has completed two Phase II tests. Anthera raised $36 million in 2006.
Next Story: Siano raises $17.5M for mobile TV chips
Previous Story: Beacon backlash continues: Class action lawsuit filed gainst Facebook
About the Author, Anthony Ha
Anthony is VentureBeat's assistant editor, as well as its reporter on enterprise technology, cloud computing, and tech policy. Before joining VentureBeat in 2008, Anthony worked at the Hollister Free Lance, where he won awards from the California Newspaper Publishers Association for breaking news coverage and writing. He attended Stanford University and now lives in San Francisco. Reach him at anthony@venturebeat.com. You can also follow Anthony on Twitter.